Interdisciplinary Clinical Target Volume Generation for Cardiac Radioablation: Multicenter Benchmarking for the RAdiosurgery for VENtricular TAchycardia (RAVENTA) Trial

Boda-Heggemann, Judit; Blanck, Oliver; Mehrhof, Felix; Ernst, Floris; Buergy, Daniel; Fleckenstein, Jens; Tülümen, Erol; Krug, David; Siebert, Frank‐André; Zaman, Adrian; Kluge, Anne; Parwani, Abdul Shokor; Andratschke, Nicolaus; Mayinger, Michael; Ehrbar, Stefanie; Saguner, Ardan M.; Celik, Eren; Baus, Wolfgang; Stauber, Annina; Vogel, Lena; Schweikard, Achim; Budach, Volker; Dunst, Jürgen; Boldt, Leif‐Hendrik; Bonnemeier, Hendrik; Rudic, Boris

doi:10.1016/j.ijrobp.2021.01.028

Cited by 41 publications

(35 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of note, the PTV includes a safety margin for motion uncertainties, which depends on the technique used for motion compensation 5,10 . Boda-Heggemann et al published the first contouring benchmark study from the prospective RAVENTA-trial demonstrating limited inter-observer agreement as well as considerable variation in transferring the desired target volume from the electroanatomic maps to the treatment planning system 29 .…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia

et al. 2021

Self Cite

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The target for treatment is thus based on aggregating clinical and electro-anatomical information of several modalities such as (non)-invasive electrophysiology studies and cardiac imaging resulting in interobserver differences in target definition and delineation. 7 An important aspect in the definition of this target is the different anatomic orientation between cardiology-electrophysiology and radiation oncology; while in cardiology the cardiac axes determine nomenclature and deduction, in radiation oncology the standard orthogonal axes are mainly used. As a potential solution for this problem, the use of the American Heart Association (AHA) 17-segment model has previously been proposed as structured approach for the identification and subsequent targeting and treatment of the proarrhythmic region(s).…”

Section: Introductionmentioning

confidence: 99%

Standardizing the Cardiac Radioablation Targeting Workflow: Enabling Semi-Automated Angulation and Segmentation of the Heart According to the American Heart Association Segmented Model

Ree

Visser

Planken

et al. 2022

Advances in Radiation Oncology

View full text Add to dashboard Cite

“…In this series, and reflecting current worldwide experience and literature, we used a range of approaches from manual delineation methods to more sophisticated computer-assisted visualisation methods still under development. [26][27][28] The optimum dose and delivery platform for cardiac SABR is yet to be established. We used a single fraction 25 Gy regime as reported by all groups previously.…”

Section: Discussionmentioning

confidence: 99%

Cardiac stereotactic ablative radiotherapy for control of refractory ventricular tachycardia: initial UK multicentre experience

et al. 2021

View full text Add to dashboard Cite

BackgroundOptions for patients with ventricular tachycardia (VT) refractory to antiarrhythmic drugs and/or catheter ablation remain limited. Stereotactic radiotherapy has been described as a novel treatment option.MethodsSeven patients with recurrent refractory VT, deemed high risk for either first time or redo invasive catheter ablation, were treated across three UK centres with non-invasive cardiac stereotactic ablative radiotherapy (SABR). Prior catheter ablation data and non-invasive mapping were combined with cross-sectional imaging to generate radiotherapy plans with aim to deliver a single 25 Gy treatment. Shared planning and treatment guidelines and prospective peer review were used.ResultsAcute suppression of VT was seen in all seven patients. For five patients with at least 6 months follow-up, overall reduction in VT burden was 85%. No high-grade radiotherapy treatment-related side effects were documented. Three deaths (two early, one late) occurred due to heart failure.ConclusionsCardiac SABR showed reasonable VT suppression in a high-risk population where conventional treatment had failed.

show abstract

Interdisciplinary Clinical Target Volume Generation for Cardiac Radioablation: Multicenter Benchmarking for the RAdiosurgery for VENtricular TAchycardia (RAVENTA) Trial

Cited by 41 publications

References 37 publications

Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia

Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia

Standardizing the Cardiac Radioablation Targeting Workflow: Enabling Semi-Automated Angulation and Segmentation of the Heart According to the American Heart Association Segmented Model

Cardiac stereotactic ablative radiotherapy for control of refractory ventricular tachycardia: initial UK multicentre experience

Contact Info

Product

Resources

About